ScreenerHero

CRISCuris, Inc.

NAS · US · Healthcare · Biotechnology · curis.com
1.580USD-8.14%Mkt Cap: 3.83M $P/E: 0.43

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral s…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.83M $
Enterprise Value-10.16M $
Revenue (TTM)7.06M $
Gross Profit9.40M $
Net Income (TTM)-7.58M $
Revenue/Share8.895 USD
Last Price1.580 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.43
P/E (Forward)-0.27
PEG—
EV/EBITDA0.30
EV/Revenue-1.44
P/S0.55
P/B0.19
EPS (TTM)3.42
EPS (Forward)-6.01
52W Range
1.5000% of range39.00
52W High39.00 USD
52W Low1.500 USD
Profitability
Gross Margin99.52%
Oper. Margin-485.12%
EBITDA Margin0.00%
Profit Margin-80.29%
ROE-138.81%
ROA-37.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.20M $
CapEx (TTM)—
FCF Margin-195.48%
FCF Yield-360.33%
Net Debt-13.66M $
Net Debt/EBITDA0.40
Balance Sheet
Debt/Equity0.30
Current Ratio1.11
Quick Ratio1.00
Book Value/Sh8.449 USD
Cash/Share7.697 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 30, 2018
Splits
Last Split1:20
Split DateJul 6, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)42.67 USD
Upside (mean)+2600.4%
Target Range20.00 USD – 65.00 USD
$20.00+2600.4% to mean$65.00
# Analysts3
Ownership
Shares Out.2.43M
Float1.38M
Insiders8.03%
Institutions42.45%
Short Interest
Short Ratio1.1d
Short % Float6.76%
Short % Out.6.69%
Shares Short130.31K
Short (prev mo.)175.79K
Technical
SMA 505.301 (-70.2%)
SMA 20014.63 (-89.2%)
Beta3.09
S&P 52W Chg18.16%
Avg Vol (30d)224.89K
Avg Vol (10d)563.37K
Technical Indicators
RSI (14)23.3
MACD-1.1612
MACD Signal-1.0093
MACD Hist.-0.1519
BB Upper6.532 USD
BB Middle3.665 USD
BB Lower0.7972 USD
BB Width156.50%
ATR (14)0.6238 USD
Vol Ratio (20d)0.69x